Trial Profile

A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Loncastuximab tesirine (Primary) ; Idelalisib
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms LOTIS 6
Sponsors ADC Therapeutics

Most Recent Events

07 Jan 2023 This trial has been completed in Hungary (Date of the global end of the trial: 25-Nov-2022), according to the European Clinical Trials Database record.
05 Jan 2023 This trial has been completed in Poland (End Date: 25 Nov 2022) according to European Clinical Trials Database record.
09 Aug 2022 Status changed from active, no longer recruiting to discontinued, according to an ADC therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com